Loading clinical trials...
Loading clinical trials...
This study was planned to compare deferasirox and desferrioxamine in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Choosing an effective iron chelator is crucial to increasing iron chelation therapy compliance. Not much local data exists in Pakistan comparing the effectiveness of deferasirox (DFX) and desferrioxamine (DFO), so, this study would be helpful in providing baseline data and formulating new protocols for iron chelation therapy, in which DFX may be a useful oral alternative to parenteral DFO.
Age
2 - 15 years
Sex
ALL
Healthy Volunteers
No
Thalassemia Center of Hematology Department, The Children's Hospital & The Institute of Child Health
Multan, Punjab Province, Pakistan
Start Date
January 1, 2023
Primary Completion Date
September 30, 2023
Completion Date
September 30, 2023
Last Updated
June 21, 2024
142
ACTUAL participants
Deferasirox (DFX)
DRUG
Deferoxamine (DFO)
DRUG
Lead Sponsor
RESnTEC, Institute of Research
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions